Aditxt, Inc. Investing Cash Flow
Aditxt, Inc. (ADTX) reported Investing Cash Flow of -$10.38 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-05-20
- Aditxt, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$10.38K.
- Aditxt, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$13.74K.
- Aditxt, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $0.00.
- Aditxt, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was -$2.74M.
- Aditxt, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$2.44M.
- Aditxt, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$5.00M.
- Aditxt, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$14.41K.
- Aditxt, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$241.92K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$10.38K 10-Q · filed 2026-05-20 | -$24.12K derived: sum of 2 quarters · filed 2026-05-20 | -$24.12K derived: sum of 3 quarters · filed 2026-05-20 | |
| 2025-12-31 | -$13.74K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$13.74K derived: sum of 2 quarters · filed 2026-03-31 | -$2.44M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$2.42M 10-Q · filed 2025-11-18 | ||
| 2025-06-30 | -$2.42M 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.00M derived: sum of 2 quarters · filed 2026-03-31 | -$5.00M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$2.26M 10-Q · filed 2025-11-18 | ||
| 2024-06-30 | -$1.00M 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$9.36K derived: sum of 2 quarters · filed 2025-03-31 | -$9.36K derived: sum of 3 quarters · filed 2025-03-31 | -$14.41K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$9.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$9.36K derived: sum of 2 quarters · filed 2024-11-18 | -$14.41K 10-Q · filed 2024-11-18 | $165.32K derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | -$2.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$5.05K 10-Q · filed 2024-08-19 | $174.68K derived: sum of 3 quarters · filed 2024-08-19 | $262.11K derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | -$5.05K 10-Q · filed 2024-05-20 | $174.68K derived: sum of 2 quarters · filed 2024-05-20 | $262.12K derived: sum of 3 quarters · filed 2024-05-20 | $126.40K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $179.73K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $267.16K derived: sum of 2 quarters · filed 2024-04-16 | $131.45K derived: sum of 3 quarters · filed 2024-04-16 | -$241.92K 10-K · filed 2024-04-16 |
| 2022-09-30 | $87.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$48.28K derived: sum of 2 quarters · filed 2023-11-14 | -$421.64K 10-Q · filed 2023-11-14 | -$8.90M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$135.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$509.08K 10-Q · filed 2023-08-14 | -$8.99M derived: sum of 3 quarters · filed 2023-08-14 | -$16.03M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$373.37K 10-Q · filed 2023-05-15 | -$8.86M derived: sum of 2 quarters · filed 2023-05-15 | -$15.90M derived: sum of 3 quarters · filed 2023-05-15 | -$16.19M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | -$15.52M derived: sum of 2 quarters · filed 2023-04-17 | -$15.82M derived: sum of 3 quarters · filed 2023-04-17 | -$16.31M 10-K · filed 2023-04-17 |
| 2021-09-30 | -$7.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$7.34M derived: sum of 2 quarters · filed 2022-11-14 | -$7.82M 10-Q · filed 2022-11-14 | -$7.83M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$294.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$780.82K 10-Q · filed 2022-08-15 | -$790.91K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$486.45K 10-Q · filed 2022-05-16 | -$496.55K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$10.10K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$170.63K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$160.53K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |